Published in Drug Law Weekly, May 29th, 2007
The Complaint alleges, inter alia, that during the Class Period, defendants improperly marketed Amgen's anti-anemia drugs Aranesp and Epogen to doctors for off-label uses. As a result, Amgen sold several hundred million dollars worth of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.